Is Intuitive Surgical Stock Worth More Than Its Competitors?
Intuitive Surgical (ISRG) trades at 51.6x earnings, the highest in its peer group, despite a 17.6% drop. It leads in revenue growth (20.5%) and operating margin (32.3%), which is nearly double that of Globus Medical (21.4%). ISRG's revenue is mostly recurring, with instruments and accessories making up 59% of fiscal 2025 sales. Da Vinci procedures grew 14% in Q3 2026, with U.S. growth at 10% and international at 20%.
How this was made
The 30-second read
Why it matters
The article provides valuation analysis without new corporate events, offering limited trading impetus.
Market read
Primarily relevant to investors tracking surgical robotics and healthcare equipment valuations.
What to watch
Potential impact of upcoming instrument price cuts and China pricing changes not fully quantified.
Background
Intuitive Surgical's stock trades at a premium to peers, with strong operating margins but recent share price decline.
Ticker impact
Article discusses Intuitive Surgical's Q3 2026 operating margin, revenue mix and valuation multiples, providing fresh commentary on its financial metrics.
likely modest pressure as investors reassess valuation versus peers
No new earnings release or material event; the piece offers analysis of existing data.
Market effects
Highlights valuation gap in surgical robotics, may prompt peer comparison.
U.S. healthcare sector focus; limited broader impact.
Low global relevance beyond the niche medical device space.
Counterpoint
Despite high multiples, margin strength could justify premium if growth sustains.
Key entities
- CompanyIntuitive Surgical
US-listed medical device maker (ticker ISRG).
